CoolSculpting and RF for the Submental

Body Fat Disorder Clinical Trial

— CRT  

Official title:

A Feasibility Study to Explore the Safety and Efficacy of Cryolipolysis Followed by Radiofrequency Treatment for Submental and Submandibular Contouring

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03873779
• Other study ID #: ZA18-002
• Status: Active, not recruiting
• Phase: N/A
• Start date: December 18, 2018
• Est. completion date: November 2020

Study information

• Verified date: August 2020
• Source: Zeltiq Aesthetics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of sequential use of CoolSculpting (Cryolipolysis) and radiofrequency treatment of the submental and submandibular area.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 25
• Est. completion date: November 2020
• Est. primary completion date: August 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 22 Years to 65 Years

Eligibility

Inclusion Criteria

• Male or female subjects =22 years of age and =65 years of age.

• Treatment area skin fold thickness > 1cm (measured by caliper).

• Dissatisfaction with the treatment area expressed by the subject as a rating of 0, 1 or 2 using the Subject Self Rating Scale (SSRS) as determined at Screening visit.

• No weight change exceeding 5% of body weight in the preceding month.

• Agreement to maintain his/her weight (i.e., within 5%) by not making any major changes in diet or exercise routine during the course of the study.

• Subject has signed a written informed consent form

Exclusion Criteria

• Body Mass Index = 46.2 as determined at screening.

• Excessive skin laxity in the treatment area for which reduction of subcutaneous fat may, in the opinion of the investigator, result in an unacceptable aesthetic result.

• Prominent platysmal bands at rest which may interfere with assessment of treatment area.

• Evidence of any cause of enlargement in the treatment area other than localized subcutaneous fat, such as swollen lymph nodes or ptotic submandibular glands.

• Significant enlargement on the anterior neck that may prevent the proper placement of the applicator e.g. enlarged thyroid glands.

• Treatment with dermal fillers, chemical peels, radiofrequency or laser procedures that may affect contour in the treatment area within the past 6 months.

• Botulinum toxin, deoxycholic acid, or other aesthetic drug injections within the treatment area in the past 6 months.

• History of facial nerve paresis or paralysis (such as Bell's palsy).

• History of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.) or implant in or adjacent to the area of intended treatment.

• History of prior neck surgery, or prior surgery in the area of intended treatment.

• Current infection in and adjacent to treatment area.

• Known history of cryoglobulinemia, cold urticaria, cold agglutinin disease or paroxysmal cold hemoglobinuria.

• Known history of Raynaud's disease, or any known condition with a response to cold exposure that limits blood flow to the skin.

• History of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.

• Currently taking or has taken diet pills or weight control supplements within the past month.

• Any dermatological conditions, such as scars in the location of the treatment area that may interfere with the treatment or evaluation.

• Active implanted device such as a pacemaker, automatic implantable cardioverter/defibrillator (AICD), drug delivery system, or any other implantable electrical device.

• Pregnant or intending to become pregnant in the next 6 months.

• Lactating or has been lactating in the past 6 months.

• Unable or unwilling to comply with the study requirements including remaining clean shaven for all study visits.

• Currently enrolled in a clinical study of an unapproved investigational drug or device.

• Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Related Conditions & MeSH terms

• Body Fat Disorder
• Lipid Metabolism Disorders

Intervention

Device:
• The ZELTIQ System
The CoolSculpting machine will be used to perform the treatments.

Locations

Country	Name	City	State
United States	Innovation Research Center	Pleasanton	California

Sponsors (1)

Lead Sponsor	Collaborator
Zeltiq Aesthetics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of unanticipated adverse device effects (UADE). It is expected there will be zero UADE's.	The primary safety endpoint is measurement of unanticipated adverse device effects. All adverse events reported during and following the treatment will be included in the safety analysis. The frequency and proportion of subjects reporting each type of adverse event will be tabulated by relationship with the treatment and severity of the event.	12-weeks post final treatment
Secondary	Assessment of overall treatment outcome in submental and submandibular area using Subject-graded GAIS (SGAIS)	Overall improvement in the targeted area will be assessed by the subject using the GAIS at 12-weeks post-final treatment. The assessment will consist of writing the outcome as: Very much improved; much improved; improved; no change; worse; much worse; very much worse.	12-weeks post final treatment